R
evvity Inc. (NYSE: RVTY), one of Massachusetts’ largest publicly traded firms, is advancing a workforce reduction plan that includes closing a second state site and additional layoffs, as first reported by the Boston Business Journal. A WARN filing shows the company will permanently shut its Lawrence plant at 360 Merrimack St., affecting 51 employees. While some may transfer to the Hopkinton campus, layoffs could begin in December 2025, with most completed by January 2026. This follows the earlier announcement of the Boston South End facility at 549 Albany St. shutting down, where 74 positions will be eliminated between November 2025 and December 2026. Revvity’s spokesperson said the moves aim to consolidate operations from Lawrence and Boston into Hopkinton to streamline its footprint, offering relocation options and emphasizing support for affected staff. The company, spun out of PerkinElmer, ranks 35th among Massachusetts public companies and employed 759 in‑state workers as of April 2025, with a global workforce of about 11,000. Its core activities span biomarker discovery, diagnostics, imaging, informatics, and predictive analytics—key sectors in personalized medicine. Despite this focus, Revvity has faced financial strain; its shares have dropped over 26% since the start of 2025, and the market cap closed at $10.64 billion. The consolidation mirrors a broader biotech trend of shrinking physical footprints to boost efficiency amid tighter capital markets and economic uncertainty. While the company reaffirms its commitment to Massachusetts, the closures signal a notable shift in the state’s biotech employment landscape, potentially affecting local economies and supply chains. The majority of transitions are slated for Q1 2026, though some employees may experience impacts as early as next month. No further restructuring plans have been disclosed. Revvity’s decision follows a broader industry shift toward leaner operations, as companies seek to reduce overhead and focus on research and development. The company’s leadership has emphasized that the consolidation will allow it to concentrate resources on its core product pipeline, which includes diagnostic assays and imaging platforms. Employees affected by the closures will receive severance packages and outplacement services, and has pledged to maintain a presence in Massachusetts in facilities. This report is based on original coverage by the Boston Business Journal.